During the past few years increasing use is being made of high-dose, intravenous glucocorticoid (pulse) therapy in various rheumatic diseases. Reports of pulse therapy for disease flares of systemic lupus erythematosus,' rheumatoid arthritis,2 and spondyloarthropathy3 have all been published. Pulse therapy usually employs 1-0 g boluses of methylprednisolone sodium succinate given for one to 3 successive days, infused over a time interval ranging from 30 minutes to 2 hours per bolus. Very little information is available on the optimal total dose, the frequency of intermittent pulses, or the effect on the long-term course of the disease. The patient was a 26-year-old blacksmith with a one-year history of radiographically confirmed sacroiliitis. For 6 months prior to his initial visit here he had been largely incapacitated by his low back pain. He was unable to work half-time and was having substantial sleep disturbance from the pain. Various nonsteroidal drugs, including phenylbutazone and indomethacin, had provided minimal subjective relief and caused recurrent gastrointestinal upset.
He was first seen here in mid-July 1981, given intramuscular MPA, and started on naproxen 375 mg twice a day with food. Within 24 hours his pain had almost entirely cleared, he was able to sleep without difficulty, and he returned to full-time work (actually, double shifts). Two weeks later, because of some recurrence of pain, the intramuscular MPA was repeated, with some additional subjective response, though clearly less dramatic than after the first injection. When last seen, in early October 1981, his only 308 
Discussion
Treatment with intramuscular methylprednisolone acetate may offer several advantages over higherdose, intravenous pulse therapies. The intramuscular route described here employs a lower total dose, is less expensive, and by-passes the need for intravenous administration. Moreover compliance is assured, and the possibility of gastrointestinal toxicity from oral steroid administration is eliminated. The details of short-and long-term efficacy and the optimal dosage and schedule remain to be clarified for all forms of bolus parenteral therapy in rheumatic diseases. However, persistent use of 1 g of intravenous methylprednisolone may not be justified. Several of the clinical responses reported here to the lower dose of intramuscular MPA were quite striking.
Although large intravenous boluses of methylprednisolone succinate were initially thought to be relatively free of significant side effects, these have been described.47 The overall incidence of side effects with intravenous pulse therapy may exceed 50 % ,' including occasional reports of sudden death.5 6 Certainly the latter should temper enthusiasm for intravenous pulse therapy in patients with non-life-threatening disease.' Occasional anaphylactic reactions, usually associated with the succinate esters of methylprednisolone, have been reported.8 Use of the acetate might circumvent this problem.
The main use of the intramuscular MPA bolus described in this report may be in managing acute or subacute disease flares while simultaneously a more effective long-term conventional therapy is started. Certainly a remission of the disease might occur in some cases without alteration to the treatment or any addition to it. The intramuscular route is suitable for outpatients.
The observations reported here are uncontrolled. 
